Design, synthesis and characterisation of new chimeric ruthenium(II)-gold(I) complexes as improved cytotoxic agents.

Two heterobimetallic complexes, i.e. [RuCl2(p-cymene)(μ-dppm)AuC] (1) and [RuCl2(p-cymene)(μ-dppm)Au(S-thiazoline)] (3), based on known cytotoxic [Ru(p-cymene)Cl2(PR3)] and [AuX(PR3)] (X = Cl, SR) molecular scaffolds, with the diphosphane linker 1,1-bis(diphenylphosphino)methane, dppm, were conveniently prepared and characterised. Remarkably, the new compounds manifested a more favourable in vitro pharmacological profile toward cancer cells than individual ruthenium and gold species being either more cytotoxic or more selective. The interactions of the studied compounds with (pBR322) DNA and their inhibitory effects on cathepsin B were also assessed. In addition, their reactivity toward suitable models of protein targets was explored and clear evidence gained for disruption of the bimetallic motif and for protein binding of monometallic fragments. Overall, the data reported here strongly support the concept of multifunctional heterometallic compounds as "improved" candidate agents for cancer treatment. The mechanistic and pharmacological implications of the present findings are discussed.

[1]  A. Prokop,et al.  Gold(I) thiotetrazolates as thioredoxin reductase inhibitors and antiproliferative agents. , 2015, Dalton transactions.

[2]  A. Casini,et al.  New heteronuclear gold(I)-platinum(II) complexes with cytotoxic properties: are two metals better than one? , 2014, Journal of inorganic biochemistry.

[3]  Alberto Martínez,et al.  In Vitro and in Vivo Evaluation of Water-Soluble Iminophosphorane Ruthenium(II) Compounds. A Potential Chemotherapeutic Agent for Triple Negative Breast Cancer , 2014, Journal of medicinal chemistry.

[4]  J. Ramos,et al.  Organometallic Titanocene–Gold Compounds as Potential Chemotherapeutics in Renal Cancer. Study of their Protein Kinase Inhibitory Properties , 2014, Organometallics.

[5]  A. Griffioen,et al.  In vivo anti-tumor activity of the organometallic ruthenium(II)-arene complex [Ru(η6-p-cymene)Cl2(pta)] (RAPTA-C) in human ovarian and colorectal carcinomas , 2014 .

[6]  I. Marzo,et al.  Luminescent Re(i) and Re(i)/Au(i) complexes as cooperative partners in cell imaging and cancer therapy , 2014 .

[7]  U. Rothlisberger,et al.  Ligand substitutions between ruthenium–cymene compounds can control protein versus DNA targeting and anticancer activity , 2014, Nature Communications.

[8]  A. Casini,et al.  A golden future in medicinal inorganic chemistry: the promise of anticancer gold organometallic compounds. , 2014, Dalton transactions.

[9]  P. Dyson,et al.  Opening the lid on piano-stool complexes: An account of ruthenium(II)–arene complexes with medicinal applications , 2014 .

[10]  R. Scopelliti,et al.  Efficient and Rapid Synthesis of Chlorido‐Bridged Half‐Sandwich Complexes of Ruthenium, Rhodium, and Iridium by Microwave Heating , 2013 .

[11]  A. Casini,et al.  Potential anticancer heterometallic Fe-Au and Fe-Pd agents: initial mechanistic insights. , 2013, Journal of medicinal chemistry.

[12]  S. Tabassum,et al.  A Chloro-Bridged Heterobimetallic (η6-Arene)ruthenium–Organotin Complex as an Efficient Topoisomerase Iα Inhibitor , 2013 .

[13]  V. Moreno,et al.  [RuCl2(η6-p-cymene)(P*)] and [RuCl2(κ-P*-η6-arene)] Complexes Containing P-Stereogenic Phosphines. Activity in Transfer Hydrogenation and Interactions with DNA , 2013 .

[14]  C. Che,et al.  A dinuclear cyclometalated gold(III)–phosphine complex targeting thioredoxin reductase inhibits hepatocellular carcinoma in vivo , 2013 .

[15]  Lara C. Spencer,et al.  Platinum(II) and gold(I) complexes based on 1,1′-bis(diphenylphosphino)metallocene derivatives: Synthesis, characterization and biological activity of the gold complexes , 2012 .

[16]  L. Massai,et al.  Protein metalation by metal-based drugs: reactions of cytotoxic gold compounds with cytochrome c and lysozyme , 2012, JBIC Journal of Biological Inorganic Chemistry.

[17]  Louis J. Farrugia,et al.  WinGX and ORTEP for Windows: an update , 2012 .

[18]  A. Casini,et al.  Gold(I) carbene complexes causing thioredoxin 1 and thioredoxin 2 oxidation as potential anticancer agents. , 2012, Journal of medicinal chemistry.

[19]  R. Gust,et al.  Synthesis, characterization, and in vitro studies of bis[1,3-diethyl-4,5-diarylimidazol-2-ylidene]gold(I/III) complexes. , 2012, Journal of medicinal chemistry.

[20]  A. Casini,et al.  Multinuclear cytotoxic metallodrugs: physicochemical characterization and biological properties of novel heteronuclear gold-titanium complexes. , 2011, Inorganic chemistry.

[21]  Armando Varela-Ramírez,et al.  Titanocene-phosphine derivatives as precursors to cytotoxic heterometallic TiAu2 and TiM (M = Pd, Pt) compounds. Studies of their interactions with DNA. , 2011, Inorganic chemistry.

[22]  S. Berners‐Price,et al.  Gold compounds as therapeutic agents for human diseases. , 2011, Metallomics : integrated biometal science.

[23]  F. Pelletier,et al.  Development of bimetallic titanocene-ruthenium-arene complexes as anticancer agents: relationships between structural and biological properties. , 2010, Journal of medicinal chemistry.

[24]  A. Casini,et al.  Gold compounds as anticancer agents: chemistry, cellular pharmacology, and preclinical studies , 2010, Medicinal research reviews.

[25]  P. Dyson,et al.  Synthesis and anticancer activity of chalcogenide derivatives and platinum(II) and palladium(II) complexes derived from a polar ferrocene phosphanyl–carboxamide , 2010 .

[26]  R. Britto,et al.  Cytotoxicity of half sandwich ruthenium(II) complexes with strong hydrogen bond acceptor ligands and their mechanism of action. , 2010, Journal of inorganic biochemistry.

[27]  A. Casini,et al.  Thioredoxin reductase: A target for gold compounds acting as potential anticancer drugs , 2009 .

[28]  A. Casini,et al.  Emerging protein targets for anticancer metallodrugs: inhibition of thioredoxin reductase and cathepsin B by antitumor ruthenium(II)-arene compounds. , 2008, Journal of medicinal chemistry.

[29]  J. Mague,et al.  Synthesis and characterization of RuII/AuI, PdII/AuI, PdII/2AuI, PtII/2AuI and CuI/2AuI heterometallic complexes of cyclodiphosphazane cis-{(o-MeOC6H4O)P(μ-NtBu)}2 , 2008 .

[30]  A. Laguna,et al.  Tetrahydrothiophene)Gold(I) or Gold(III) Complexes , 2007 .

[31]  J. Schellens,et al.  A Phase I and Pharmacological Study with Imidazolium-trans-DMSO-imidazole-tetrachlororuthenate, a Novel Ruthenium Anticancer Agent , 2004, Clinical Cancer Research.

[32]  D. Hanahan,et al.  Cathepsin cysteine proteases are effectors of invasive growth and angiogenesis during multistage tumorigenesis. , 2004, Cancer cell.

[33]  P. Dyson,et al.  The effect of pH on the hydrogenation of benzene in an aqueous biphase using a ruthenium catalyst , 2003 .

[34]  F. Allen.  The Cambridge Structural Database: a quarter of a million crystal structures and rising. , 2002, Acta crystallographica. Section B, Structural science.

[35]  Bonnie F. Sloane,et al.  Unraveling the role of proteases in cancer. , 2000, Clinica chimica acta; international journal of clinical chemistry.

[36]  Maria Cristina Burla,et al.  SIR97: a new tool for crystal structure determination and refinement , 1999 .

[37]  Pankaj Sharma,et al.  Synthesis, characterization, reactivity and structure of some mono and binuclear (η6-p-cymene)ruthenium(II) complexes , 1998 .

[38]  Louis J. Farrugia,et al.  ORTEP-3 for Windows - a version of ORTEP-III with a Graphical User Interface (GUI) , 1997 .

[39]  M. Nardelli,et al.  PARST95 – an update to PARST: a system of Fortran routines for calculating molecular structure parameters from the results of crystal structure analyses , 1995 .

[40]  U. Schubert,et al.  Gold‐Komplexe von Diphosphinomethanen, II. Synthese und Kristallstruktur achtgliedriger Ringverbindungen von Gold(I) mit Au–Au‐Wechselwirkung , 1977 .

[41]  J. Schellens,et al.  Approaching tumour therapy beyond platinum drugs: status of the art and perspectives of ruthenium drug candidates. , 2012, Journal of inorganic biochemistry.

[42]  Anna F. A. Peacock,et al.  In vivo tumour and metastasis reduction and in vitro effects on invasion assays of the ruthenium RM175 and osmium AFAP51 organometallics in the mammary cancer model. , 2010, Journal of inorganic biochemistry.

[43]  G. Sheldrick.  A short history of SHELX. , 2008, Acta crystallographica. Section A, Foundations of crystallography.

[44]  P. Parsons,et al.  A gel mobility shift assay for probing the effect of drug-DNA adducts on DNA-binding proteins. , 1997, Methods in molecular biology.